中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2013年
5期
383-386
,共4页
李蒙妍%尚革%赵化荣%胡尔西旦·尼牙孜%刘攀%张宋安%包永星
李矇妍%尚革%趙化榮%鬍爾西旦·尼牙孜%劉攀%張宋安%包永星
리몽연%상혁%조화영%호이서단·니아자%류반%장송안%포영성
脑肿瘤/术后放射疗法%脑肿瘤/术后放化疗法%预后
腦腫瘤/術後放射療法%腦腫瘤/術後放化療法%預後
뇌종류/술후방사요법%뇌종류/술후방화요법%예후
Brain neoplasms/postoperative radiotherapy%Brain neoplasms/postoperative radiochemotherapy%Prognosis
目的 评价Ⅲ、Ⅳ级脑胶质瘤术后放化疗的疗效及预后因素.方法 回顾分析2007-2012年间119例Ⅲ、Ⅳ级脑胶质瘤术后放疗或放化疗患者的临床资料,其中单纯放疗49例,放疗联合亚硝脲类化疗21例,放疗联合替莫唑胺化疗49例.采用Kaplan-Meier法计算总生存率和复发率,Cox模型多因素预后分析.结果 随访率为94.1%,随访时间满1、2年样本数分别为53、10例.总复发率69.7%.1、2年总生存率分别为44.5%、8.4%.多因素分析显示年龄、术前有无癫痫发作、肿瘤切除程度、放疗联合替莫唑胺化疗均是影响肿瘤复发的因素(P =0.002、0.005、0.000、0.000),上述因素加上肿瘤病理分级是影响患者生存的因素(P =0.006、0.010、0.000、0.000、0.001).结论 Ⅲ、Ⅳ级脑胶质瘤术后患者放疗联合替莫唑胺化疗可取得较好疗效,同时年龄< 60岁、术前无癫痫发作、肿瘤全切、肿瘤病理分级Ⅲ级是影响恶性胶质瘤患者长期生存的有益因素.
目的 評價Ⅲ、Ⅳ級腦膠質瘤術後放化療的療效及預後因素.方法 迴顧分析2007-2012年間119例Ⅲ、Ⅳ級腦膠質瘤術後放療或放化療患者的臨床資料,其中單純放療49例,放療聯閤亞硝脲類化療21例,放療聯閤替莫唑胺化療49例.採用Kaplan-Meier法計算總生存率和複髮率,Cox模型多因素預後分析.結果 隨訪率為94.1%,隨訪時間滿1、2年樣本數分彆為53、10例.總複髮率69.7%.1、2年總生存率分彆為44.5%、8.4%.多因素分析顯示年齡、術前有無癲癇髮作、腫瘤切除程度、放療聯閤替莫唑胺化療均是影響腫瘤複髮的因素(P =0.002、0.005、0.000、0.000),上述因素加上腫瘤病理分級是影響患者生存的因素(P =0.006、0.010、0.000、0.000、0.001).結論 Ⅲ、Ⅳ級腦膠質瘤術後患者放療聯閤替莫唑胺化療可取得較好療效,同時年齡< 60歲、術前無癲癇髮作、腫瘤全切、腫瘤病理分級Ⅲ級是影響噁性膠質瘤患者長期生存的有益因素.
목적 평개Ⅲ、Ⅳ급뇌효질류술후방화료적료효급예후인소.방법 회고분석2007-2012년간119례Ⅲ、Ⅳ급뇌효질류술후방료혹방화료환자적림상자료,기중단순방료49례,방료연합아초뇨류화료21례,방료연합체막서알화료49례.채용Kaplan-Meier법계산총생존솔화복발솔,Cox모형다인소예후분석.결과 수방솔위94.1%,수방시간만1、2년양본수분별위53、10례.총복발솔69.7%.1、2년총생존솔분별위44.5%、8.4%.다인소분석현시년령、술전유무전간발작、종류절제정도、방료연합체막서알화료균시영향종류복발적인소(P =0.002、0.005、0.000、0.000),상술인소가상종류병리분급시영향환자생존적인소(P =0.006、0.010、0.000、0.000、0.001).결론 Ⅲ、Ⅳ급뇌효질류술후환자방료연합체막서알화료가취득교호료효,동시년령< 60세、술전무전간발작、종류전절、종류병리분급Ⅲ급시영향악성효질류환자장기생존적유익인소.
Objective To evaluate the treatment outcome and prognostic factors in patients with grade Ⅲ/Ⅳ glioma following postoperative chemoradiotherapy.Methods A retrospective analysis was performed on the medical records of 119 patients with grade Ⅲ/Ⅳ glioma who received treatment in our hospital from January 2007 to April 2012.Of the 119 patients,49 received radiotherapy alone,21 received radiotherapy combined with nitrosoureas,and 49 received radiotherapy combined with temozolomide.The Kaplan-Meier method was used to calculate overall survival (OS) rates and recurrence rates.The Cox regression model was used for multivariate prognostic analysis.Results The follow-up rate was 94.1%.Fifty-three patients were followed up for at least 1 year,and 10 for at least 2 years.The overall recurrence rate was 69.7%.The 1-and 2-year OS rates were 44.5% and 8.4%,respectively.The multivariate analysis showed that age,presence or absence of seizures before surgery,extent of tumor resection,and radiotherapy plus concurrent and adjuvant temozolomide were the main prognostic factors for tumor recurrence (P =0.002,0.005,0.000,and 0.000).The above factors and the pathological grade of tumor were the independent prognostic factors for patients' survival (P =0.006,0.010,0.000,0.000,and 0.001).Conclusions Postoperative radiotherapy plus concurrent and adjuvant temozolomide produce a good clinical effect in patients with grade Ⅲ/Ⅳ glioma.Age of < 60 years,no seizures before surgery,total tumor resection,and pathological grade Ⅲ of tumor are the favorable prognostic factors for the long-term survival in patients with malignant glioma.